Benzophenone Semicarbazones as Potential alpha-glucosidase and Prolyl Endopeptidase Inhibitor: In-vitro free radical scavenging, enzyme inhibition, mechanistic, and molecular docking studies
$α$-glucosidase and prolylendopeptidase has altered expression and activity patterns in neurological disease, type 2diabetes respectively and several cancers. Here we screened a series 1-29 benzophenone semicarbazone derivatives for in vitro free radical scavenging, alpha-glucosidase and prolylendopeptidase inhibition activities. Seven derivatives were identified as potential free radical scavengers, 14 as alpha-glucosidase, and 9 as prolylendopeptidase inhibitors. Kinetic studies on the most promising inhibitors were performed. Compounds 23, 27, 25 and 28 were found as inhibitor of alpha-glucosidase, while compound 26 inhibited both prolylendopeptidase and alpha-glucosidase. The binding modes and binding free energy of the multi targeted inhibitor 26 were predicted by molecular docking studies. These results provide insights on prolylendopeptidase and alpha-glucosidase inhibition of compound 26 for further development as therapeutic agents for neoplastic, neurological, and endocrine disorders.